Amylin (AMLN) Won't Comment on Takeover Reports
Tweet
Share
E-mailGet Alerts AMLN Hot Sheet
Join SI Premium – FREE
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) has declined to comment on reports this morning that it is the target of a $3.5 billion takeover bid from Bristol-Myers Squibb (NYSE: BMY).
Company spokeswoman Alice Izzo said, "as a matter of company policy, Amylin does not comment on market rumors or speculation."
Shares of Amylin Pharmaceuticals are up 44 percent early Wednesday on the reports.
Company spokeswoman Alice Izzo said, "as a matter of company policy, Amylin does not comment on market rumors or speculation."
Shares of Amylin Pharmaceuticals are up 44 percent early Wednesday on the reports.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bernstein on whether Hershey (HSY) could eventually step up to buy Mondelez (MDLZ)
- Callan JMB unit to acquire Reger Oil's Williston Basin assets
- Holcim said to acquire part of James Hardie's EU business
Create E-mail Alert Related Categories
Mergers and Acquisitions, RumorsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
